Covid-19: Swissmedic adapts Inspections
Recommendation

17/18 June 2026
Copenhagen, Denmark
Supervision of the Pharmaceutical Quality System: Challenges and Opportunities
Owing to the new situation regarding the COVID-19 pandemic and the differing measures introduced by the various cantons, Swissmedic has decided to adapt the way it carries out inspections. Inspections in the healthcare field will only be performed after prior clarification of possible COVID-19-related capacity problems.
The inspections may be carried out while observing the recommended protective measures - either (partly) by means of remote assessments or at a later point in time. Safety assessments - whether non-routine and scheduled and "for cause", or routine and scheduled but process-specific - will generally take place on site. If inspections are carried out on site, participants must organise the necessary safety precautions for the inspections (meeting rooms with sufficient space, restricted participant numbers, provision of electronic resources such as projectors for document assessment, plus face masks, sanitisers, etc.).
Source: Swissmedic
Related GMP News
03.06.2026In-use Storage Time of Reconstituted Medicines
28.05.2026New EMA Q&A on the Implementation of 3DP Technology
28.05.2026EMA publishes Presentations on Contractual Agreements in Clinical Trials
28.05.2026UK Substantial Modifications Pilot
07.05.2026What are the GMP Requirements for Investigational Medicinal Products (IMPs)?


